References
1. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Washington, DC: Office of Disease Prevention and Health Promotion; 1996.
2. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services: An
Assessment of the Effectiveness of 169 Interventions. Baltimore: Williams &
Wilkins; 1989.
3. Pietrangelo A. Hereditary hemochromatosis—a new look at an old disease. N Engl J Med 2004;350:2383-97. [PMID: 15175440]
4. Adams P, Brissot P, Powell LW. EASL International Consensus Conference
on Haemochromatosis. J Hepatol 2000;33:485-504. [PMID: 11020008]
5. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med
1993;328:1616-20. [PMID: 8110209]
6. Powell LW, Isselbacher KJ. Hemochromatosis. In: Braunwald E, Fauci AS,
Kasper DL, Hauser SL, Long DL, Jameson JL, eds. Harrison's Principles of
Internal Medicine. New York: McGraw-Hill; 2001:2257-61.
7. DuBois S, Kowdley KV. Review article: targeted screening for hereditary
haemochromatosis in high-risk groups. Aliment Pharmacol Ther 2004;20:1-14.
[PMID: 15225165]
8. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al.
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.
Nat Genet 1996;13:399-408. [PMID: 8696333]
9. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis:
a HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001;154:193-206. [PMID: 11479183]
10. Edwards CQ, Ajioka RS, Kushner JP. Hemochromatosis: a genetic definition.
In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology,
Diagnosis and Treatment. Cambridge, United Kingdom: Cambridge
Univ Pr; 2000:8-11.
11. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH,
McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially
diverse population. N Engl J Med 2005;352:1769-78. [PMID: 15858186]
12. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of
Multiple-Cause Mortality Data. Ann Intern Med 1998;129:946-53. [PMID:
9867747]
13. Adams PC. Hemochromatosis. Clin Liver Dis 2004;8:735-53, vii. [PMID:
15464653]
14. Piperno A. Expression of iron overload in hemochromatosis. In: Barton JC,
Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and
Treatment. Cambridge, United Kingdom: Cambridge Univ Pr; 2000:177-83.
15. Baynes RD. Interactions of alcohol, iron and hemochromatosis. In: Barton
JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis
and Treatment. Cambridge, United Kingdom: Cambridge Univ Pr; 2000:468-74.
16. Njajou OT, Alizadeh BZ, van Duijn CM. Is genetic screening for hemochromatosis
worthwhile? Eur J Epidemiol 2004;19:101-8. [PMID: 15074564]
17. Brissot P. Clinical spectrum of hepatic disease in hemochromatosis. In: Barton
JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis
and Treatment. Cambridge, United Kingdom: Cambridge Univ Pr; 2000:
250-7.
18. Sham RL, Raubertas RF, Braggins C, Cappuccio J, Gallagher M, Phatak
PD. Asymptomatic hemochromatosis subjects: genotypic and phenotypic pro-files. Blood 2000;96:3707-11. [PMID: 11090050]
19. Hemochromatosis for Health Care Professionals. Diagnostic testing protocol.
Centers for Disease Control and Prevention. Accessed at www.cdc.gov/hemochromatosis/training/diagnostic_testing/testing_protocol.htm on 27 September
2005.
20. Adams PC. Is there a threshold of hepatic iron concentration that leads to
cirrhosis in C282Y hemochromatosis? Am J Gastroenterol 2001;96:567-9.
[PMID: 11232708]
21. Baldus WP, Batts KP, Brandhagen DJ. Liver biopsy in hemochromatosis.
In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology,
Diagnosis and Treatment. Cambridge, United Kingdom: Cambridge Univ Pr;
2000:187-99.
22. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer
G. Survival and causes of death in cirrhotic and in noncirrhotic patients
with primary hemochromatosis. N Engl J Med 1985;313:1256-62. [PMID:
4058506]
23. Strohmeyer G, Niederau C, Stremmel W. Survival and causes of death in
hemochromatosis. Observations in 163 patients. Ann N Y Acad Sci 1988;526:245-57. [PMID: 3389643]
24. Wojcik JP, Speechley MR, Kertesz AE, Chakrabarti S, Adams PC. Natural
history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol 2002;16:297-302. [PMID: 12045778]
25. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary
hemochromatosis. Gastroenterology 1991;101:368-72. [PMID: 2065912]
26. Eijkelkamp EJ, Yapp TR, Powell LW. HFE-associated hereditary hemochromatosis.
Can J Gastroenterol 2000;14:121-5. [PMID: 10694284]
27. Cadet E, Capron D, Gallet M, Omanga-Leke ML, Boutignon H, Julier C,
et al. Reverse cascade screening of newborns for hereditary haemochromatosis: a
model for other late onset diseases? J Med Genet 2005;42:390-5. [PMID:
15863667]
28. Brown AS, Gwinn M, Cogswell ME, Khoury MJ. Hemochromatosisassociated
morbidity in the United States: an analysis of the National Hospital
Discharge Survey, 1979-1997. Genet Med 2001;3:109-11. [PMID: 11280947]
29. Ajioka RS, Kushner JP. Hereditary hemochromatosis. Semin Hematol 2002;39:235-41. [PMID: 12382198]
30. McDonnell SM, Witte DL, Cogswell ME, McIntyre R. Strategies to increase
detection of hemochromatosis. Ann Intern Med 1998;129:987-92.
[PMID: 9867752]
31. Asberg A, Hveem K, Thorstensen K, Ellekjter E, Kannelonning K, Fjosne
U, et al. Screening for hemochromatosis: high prevalence and low morbidity in
an unselected population of 65,238 persons. Scand J Gastroenterol 2001;36:1108-15. [PMID: 11589387]
32. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G3
A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8. [PMID: 11812557]
33. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis:
a unifying analysis of published intervention trials. J Med Screen
1996;3:178-84. [PMID: 9041481]
34. Cogswell ME, McDonnell SM, Khoury MJ, Franks AL, Burke W, Brittenham
G. Iron overload, public health, and genetics: evaluating the evidence for
hemochromatosis screening. Ann Intern Med 1998;129:971-9. [PMID:
9867750]
35. McDonnell SM, Parrish RG. Hereditary hemochromatosis and its elusive
natural history. Arch Intern Med 2003;163:2421-3; author reply 2427. [PMID:
14609775]
36. Cogswell ME, Burke W, McDonnell SM, Franks AL. Screening for hemochromatosis.
A public health perspective. Am J Prev Med 1999;16:134-40.
[PMID: 10343890]
37. Phatak PD, Sham RL, Raubertas RF, Dunnigan K, O'Leary MT, Braggins
C, et al. Prevalence of hereditary hemochromatosis in 16031 primary care patients.
Ann Intern Med 1998;129:954-61. [PMID: 9867748]
38. Niederau C, Niederau CM, Lange S, Littauer A, Abdel-Jalil N, Maurer M,
et al. Screening for hemochromatosis and iron deficiency in employees and primary
care patients in Western Germany. Ann Intern Med 1998;128:337-45.
[PMID: 9490593]
39. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice
guideline development task force of the College of American Pathologists. Hereditary
hemochromatosis. Clin Chim Acta 1996;245:139-200. [PMID:
8867884]
40. Brittenham GM, Franks AL, Rickles FR. Research priorities in hereditary
hemochromatosis. Ann Intern Med 1998;129:993-6. [PMID: 9867753]
41. Waalen J, Nordestgaard BG, Beutler E. The penetrance of hereditary hemochromatosis.
Best Pract Res Clin Haematol 2005;18:203-20. [PMID:
15737885]
42. Feldman M, Tschumy WO, Friedman LS, Sleisenger MH. Sleisenger &
Fordtran's Gastrointestinal and Liver Disease, 7th ed. New York: Elsevier; 2002.
43. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001;33:1321-8. [PMID: 11343262]
44. McLaren CE, Barton JC, Adams PC, Harris EL, Acton RT, Press N, et al.
Hemochromatosis and Iron Overload Screening (HEIRS) study design for an
evaluation of 100,000 primary care-based adults. Am J Med Sci 2003;325:53-62. [PMID: 12589228]
45. Powell LW, George DK, McDonnell SM, Kowdley KV. Diagnosis of
hemochromatosis. Ann Intern Med 1998;129:925-31. [PMID: 9867744]
46. Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Whittall DE. Evolution of
untreated hereditary hemochromatosis in the Busselton population: a 17-year
study. Mayo Clin Proc 2004;79:309-13. [PMID: 15008603]
47. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard
BG. Hemochromatosis mutations in the general population: iron overload progression
rate. Blood 2004;103:2914-9. [PMID: 15070663]
48. Beutler E, Felitti V, Ho NJ, Gelbart T. Relationship of body iron stores to
levels of serum ferritin, serum iron, unsaturated iron binding capacity and transferrin
saturation in patients with iron storage disease. Acta Haematol 2002;107:145-9. [PMID: 11978935]
49. Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on
measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000;133:329-37. [PMID: 10979877]
50. Waalen J, Felitti V, Gelbart T, Ho NJ, Beutler E. Penetrance of hemochromatosis.
Blood Cells Mol Dis 2002;29:418-32. [PMID: 12678056]
51. Deugnier Y, Jouanolle AM, Chaperon J, Moirand R, Pithois C, Meyer JF,
et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked
haemochromatosis: a study of 9396 French people. Br J Haematol 2002;118:1170-8. [PMID: 12199803]
52. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A
population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24. [PMID: 10471457]
53. Burt MJ, George PM, Upton JD, Collett JA, Frampton CM, Chapman
TM, et al. The significance of haemochromatosis gene mutations in the general
population: implications for screening. Gut 1998;43:830-6. [PMID: 9824612]
54. Distante S, Berg JP, Lande K, Haug E, Bell H. High prevalence of the
hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian
population in the city of Oslo, and its phenotypic expression. Scand J
Gastroenterol 1999;34:529-34. [PMID: 10423072]
55. McDonnell SM, Hover A, Gloe D, Ou CY, Cogswell ME, Grummer-Strawn L. Population-based screening for hemochromatosis using phenotypic
and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Am J Med 1999;107:30-7. [PMID: 10403350]
56. Delatycki MB, Allen KJ, Nisselle AE, Collins V, Metcalfe S, du Sart D, et
al. Use of community genetic screening to prevent HFE-associated hereditary
haemochromatosis. Lancet 2005;366:314-6. [PMID: 16039334]
57. Barton JC, Rothenberg BE, Bertoli LF, Acton RT. Diagnosis of hemochromatosis
in family members of probands: a comparison of phenotyping and HFE
genotyping. Genet Med 1999;1:89-93. [PMID: 11336458]
58. Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ,
et al. Screening for hemochromatosis in asymptomatic subjects with or without a
family history. Arch Intern Med 2006;166:294-301. [PMID: 16476869]
59. Bomford A, Williams R. Long term results of venesection therapy in idiopathic
haemochromatosis. Q J Med 1976;45:611-23. [PMID: 188063]
60. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer
G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19. [PMID: 8613000]
61. Cadet E, Capron D, Perez AS, Crepin SN, Arlot S, Ducroix JP, et al. A
targeted approach significantly increases the identification rate of patients with
undiagnosed haemochromatosis. J Intern Med 2003;253:217-24. [PMID:
12542563]
62. Waalen J, Felitti V, Gelbart T, Ho NJ, Beutler E. Prevalence of coronary
heart disease associated with HFE mutations in adults attending a health appraisal
center. Am J Med 2002;113:472-9. [PMID: 12427496]
63. Poullis A, Moodie SJ, Ang L, Finlayson CJ, Levin GE, Maxwell JD. Routine
transferrin saturation measurement in liver clinic patients increases detection
of hereditary haemochromatosis. Ann Clin Biochem 2003;40:521-7. [PMID:
14503989]
64. Moodie SJ, Ang L, Stenner JM, Finlayson C, Khotari A, Levin GE, et al.
Testing for haemochromatosis in a liver clinic population: relationship between
ethnic origin, HFE gene mutations, liver histology and serum iron markers. Eur
J Gastroenterol Hepatol 2002;14:223-9. [PMID: 11953685]
65. Willis G, Scott DG, Jennings BA, Smith K, Bukhari M, Wimperis JZ.
HFE mutations in an inflammatory arthritis population. Rheumatology (Oxford) 2002;41:176-9. [PMID: 11886966]
66. Swinkels DW, Aalbers N, Elving LD, Bleijenberg G, Swanink CM, van der
Meer JW. Primary haemochromatosis: a missed cause of chronic fatigue syndrome?
Neth J Med 2002;60:429-33. [PMID: 12685490]
67. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM,
et al. Current methods of the US Preventive Services Task Force: a review of the
process. Am J Prev Med 2001;20:21-35. [PMID: 11306229]
68. The Cochrane Non-Randomised Studies Methods Group. Accessed at www.cochrane.dk/nrsmg on 18 April 2005.
69. Phatak PD, Ryan DH, Cappuccio J, Oakes D, Braggins C, Provenzano K,
et al. Prevalence and penetrance of HFE mutations in 4865 unselected primary
care patients. Blood Cells Mol Dis 2002;29:41-7. [PMID: 12482402]
70. Adams PC, Chakrabarti S. Genotypic/phenotypic correlations in genetic
hemochromatosis: evolution of diagnostic criteria. Gastroenterology 1998;114:319-23. [PMID: 9453492]
71. Adams PC, Kertesz AE, McLaren CE, Barr R, Bamford A, Chakrabarti S.
Population screening for hemochromatosis: a comparison of unbound iron-binding
capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary
blood donors. Hepatology 2000;31:1160-4. [PMID: 10796893]
72. Sanchez M, Villa M, Ingelmo M, Sanz C, Bruguera M, Ascaso C, et al.
Population screening for hemochromatosis: a study in 5370 Spanish blood donors.
J Hepatol 2003;38:745-50. [PMID: 12763366]
73. Chambers V, Sutherland L, Palmer K, Dalton A, Rigby AS, Sokol R, et al.
Haemochromatosis-associated HFE genotypes in English blood donors: age-related
frequency and biochemical expression. J Hepatol 2003;39:925-31. [PMID:
14642607]
74. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for
hereditary hemochromatosis. Rockville, MD: Agency for Healthcare Research
and Quality; 2006.
75. Williams R, Smith PM, Spicer EJ, Barry M, Sherlock S. Venesection therapy
in idiopathic haemochromatosis. An analysis of 40 treated and 18 untreated
patients. Q J Med 1969;38:1-16. [PMID: 4303815]
76. McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams
PC, et al. A survey of 2,851 patients with hemochromatosis: symptoms and
response to treatment. Am J Med 1999;106:619-24. [PMID: 10378618]
77. Harrison H, Adams PC. Hemochromatosis. Common genes, uncommon
illness? Can Fam Physician 2002;48:1326-33. [PMID: 12228962]
78. Imperatore G, Pinsky LE, Motulsky A, Reyes M, Bradley LA, Burke W.
Hereditary hemochromatosis: perspectives of public health, medical genetics, and
primary care. Genet Med 2003;5:1-8. [PMID: 12544469]
79. Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary
hemochromatosis with transferrin saturation and serum ferritin level: systematic
review for the American College of Physicians. Ann Intern Med 2005;143:522-36. [PMID: 16204165]
80. Qaseem A, Aronson M, Fitterman N, Snow V, Weiss KB, Owens DK, et
al. Screening for hereditary hemochromatosis: a clinical practice guideline from
the American College of Physicians. Ann Intern Med 2005;143:517-21. [PMID:
16204164]
81. Wetterhall SF, Cogswell ME, Kowdley KV. Public health surveillance for
hereditary hemochromatosis. Ann Intern Med 1998;129:980-6. [PMID:
9867751]
Return to Contents
Notes
Author Affiliation
a.Drs. Whitlock and Harris, Ms. Beil, and Ms. Smith: Center for Health Research, Kaiser Permanente, 3800 North
Interstate Avenue, Portland, OR 97227-1110.
b.Dr. Garlitz: Oregon Health Sciences University, 3181 SW Sam Jackson
Park Road, Portland, OR 97239-3098.
Grant Support
This study was conducted by the Oregon Evidence-based
Practice Center under contract to the Agency for Healthcare Research
and Quality, Rockville, Maryland (contract 290-02-0024, task
order no. 2).
Potential Financial Conflicts of Interest
None disclosed.
Acknowledgments
The authors thank Kevin Lutz, M.F.A., and Taryn
Cardenas for their help in preparing this manuscript, and Daphne Plaut,
MLS, for conducting the literature searches. They also thank the USPSTF,
AHRQ staff, and expert reviewers for their contribution to this project.
Return to Contents
Copyright and Source Information
This document is in the public domain within the United States. For information on reprinting, contact Randie Siegel, Director, Division of Printing and Electronic Publishing, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850.
Requests for linking or to incorporate content in electronic resources should be sent to: info@ahrq.gov.
Source: Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for Hereditary Hemochromatosis: Systematic Review. August 2006. Ann Intern Med 2006;145:209-23.
Return to Contents
Current as of August 2006
Internet Citation:
Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for Hereditary Hemochromatosis: Systematic Review for the U.S. Preventive Services Task Force. Originally published in Ann Intern Med 2006;145:209-23. August 2006. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/uspstf06/hemochromatosis/hemochrev.htm
540 Gaither Road Rockville, MD 20850